Side-by-side · Research reference

DSIPvsSermorelin

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AHuman-MechanisticDraft8/36 cited

BPhase 3Reviewed14/43 cited

DSIP

Sleep modulator · Anti-stress

100–200 mcgPer doseSchneider 1986

HumanMechanisticSchneider 1986

HoursHalf-life (est)

SQ · Pre-sleep · Daily during cycle

Sermorelin

GHRH 1-29 fragment · Short-acting

100–500 mcgPer doseMolteno 2013

Phase 3Evidence levelWalker 1994 Molteno 2013

~12 minHalf-lifeMolteno 2013

SQ · Pre-sleep · 1×/day

01Mechanism of Action

Parameter

DSIP

Sermorelin

Primary target

Multiple — modulates HPA axis + thalamic delta-wave generation (proposed)Schneider 1986

Pituitary GHRH receptorWalker 1994

Pathway

Reduced cortisol/ACTH + enhanced delta-wave EEG activity → improved sleep onset + depthSchneider 1986

GHRH-R → Gαs → cAMP → PKA → GH vesicle exocytosisWalker 1994

Downstream effect

Faster sleep onset, increased delta sleep, reduced stress response, possible anxiolytic effectSchneider 1986

Pulsatile GH release; subsequent IGF-1 elevationMolteno 2013

Feedback intact?

—

Yes — short pulse preserves feedback

Origin

Endogenous peptide first isolated from rabbit blood during delta sleep; synthesised exogenouslySchneider 1986

Unmodified active 29-AA fragment of human GHRH (1-44)Walker 1994

Antibody development

—

02Dosage Protocols

Parameter

DSIP

Sermorelin

Standard dose

100–200 mcg SQ pre-sleepSchneider 1986

100–500 mcg per injectionMolteno 2013

Frequency

Once daily, pre-sleep

Lower / starter dose

50 mcg pre-sleep

100 mcg per dose

Evidence basis

Human-mechanistic + early clinicalSchneider 1986

Phase 3 (Geref pediatric); clinical practiceWalker 1994 Molteno 2013

Duration

8–12 weeks per cycle

Reconstitution

Bacteriostatic water

Timing

30–60 min pre-sleep

Pre-sleep, fasted preferred

Half-life

Short plasma; CNS effects last hours

~12 min (plasma)Molteno 2013

Shorter than tesamorelin (~26 min) — simpler GHRH analogue.

04Side Effects & Safety

Parameter

DSIP

Sermorelin

Injection site reaction

Mild irritation

Mild erythema, transient pain

Drowsiness

Expected effect (intentional)

—

Vivid dreams

Anecdotally reported

—

Long-term safety

Limited modern RCT data

—

Pregnancy / OB

Avoid

Flushing / headache

—

Common transient effect

IGF-1 elevation

—

Modest at standard doses

Cancer risk

—

Contraindicated in active malignancy (GH/IGF-1 axis)

Glucose handling

—

Generally neutral

Absolute Contraindications

DSIP

·Pregnancy / breastfeeding
·Concurrent CNS-depressant therapy without supervision

Sermorelin

·Active malignancy
·Pregnancy / breastfeeding
·Disrupted hypothalamic-pituitary axis

Relative Contraindications

DSIP

·Severe sleep apnoea (untreated)
·Concurrent benzodiazepine / opioid use

Sermorelin

·Untreated diabetes

05Administration Protocol

Parameter

DSIP

Sermorelin

1. Reconstitution

Add 1–2 mL bacteriostatic water to vial.

Add 2 mL bacteriostatic water to 5 mg vial → 2.5 mg/mL = 250 mcg per 0.1 mL.

2. Injection site

SQ — abdomen. Rotate sites.

SQ — abdomen or thigh. Rotate sites.

3. Timing

30–60 min pre-sleep.

Pre-sleep, fasted.

4. Storage

Lyophilised: room temp. Reconstituted: refrigerate ≤30 days.

Lyophilised: room temp, light-protected. Reconstituted: refrigerate ≤30 days.

5. Needle

29–31G insulin syringe.

29–31G, 4–8 mm insulin syringe.

06Stack Synergy

DSIP

— no documented stacks

Sermorelin

+ Ipamorelin

Strong

View Ipamorelin →

Sermorelin (GHRH analogue) and ipamorelin (selective GHRP) form the prototypical GHRH+GHRP dual-axis stack at the lowest cost. Both peak within 30 min and produce a sharp physiological GH pulse without cortisol/prolactin elevation.

Sermorelin: 200–300 mcg SQ · pre-sleep
Ipamorelin: 200–300 mcg SQ · same injection
Primary benefit: Pulsatile GH stimulation, recovery, body composition

Raun 1998 Walker 1994